|
|
Article: Eye drugs put Genentech in testy spot
- Article from:
- Oakland Tribune
- Article date:
- November 8, 2007
- Author:
-
|
Copyright informationCopyright 2007 Oakland Tribune. Provided by ProQuest LLC. (Hide copyright information)
|
AVASTIN is one of Genentech's blockbuster cancer drugs. It treats
patients with colon and lung cancer, and is currently being studied
worldwide in about 300 clinical trials for more than 20 different
tumor types.
But Avastin has another use separate from cancer. In the offices
of eye doctors around the country, patients are being given the drug
off-label, or not for its FDA-approved usage, to treat a major cause
of vision loss, called neovascular age-related macular degeneration
or AMD.
That's where the situation becomes awkward for Genentech. The
company's superstar drug is going head-to-head with another drug
called Lucentis that was approved last year by the U.S. Food and
Drug ...
Related newspaper, magazine, and journal articles:
|
|
Article: Study shows Genentech's cancer fighter Avastin helps sickest patients.
Cancer Weekly;
December 21, 2004 ;
393 words
......NewsRx.net) -- Genentech Inc. said November...cancer-fighting drug Avastin helped some of the...Hal Barron, MD, Genentech's chief medical...patients receiving Avastin and chemotherapy...approved by the FDA. Genentech said it planned to discuss its newest Avastin results with the...
|
|